Showing results (31-40 of 43) with videos related to

Sort By:
Pageof 5
Redox Biology|May 17, 2025
Targeting MYOF suppresses pancreatic ductal adenocarcinoma progression by inhibiting ILF3-LCN2 signaling through disrupting OTUB1-mediated deubiquitination of ILF3Zhihui Li, Jianlei Zhang, Jiang Yin, et al.
Cell Communication and Signaling : CCS|April 27, 2025
LAMA4<sup>+</sup> CD90<sup>+</sup> eCAFs provide immunosuppressive microenvironment for liver cancer through induction of CD8<sup>+</sup> T cell senescenceJianlei Zhang, Zhihui Li, Qiong Zhang, et al.
Annals of Hematology|January 8, 2025
A prognostic index for advanced-stage extranodal natural killer/T-cell lymphoma: A multicenter studyXiaojie Fang, Fenglan Zhou, Sheng Ye, et al.
Current Opinion in Pharmacology|July 4, 2020
Modulation of gut microbiota to overcome resistance to immune checkpoint blockade in cancer immunotherapyJumin Huang, Zebo Jiang, Yuwei Wang, et al.
NPJ Breast Cancer|November 7, 2025
Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancerMengqian Ni, Daining Wang, Shu Dun, et al.
JAMA|December 17, 2014
Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trialHe Huang, Xueying Li, Jun Zhu, et al.
Cancer Science|September 12, 2025
Efficacy and Safety of T-DXd in HER2+ and Low/Zero Metastatic BCBM: A Retrospective Multicenter Real-World StudyQingru Zhou, Yuanyuan Li, Ni He, et al.
Molecular Plant|July 2, 2021
Genomic insights into the fast growth of paulownias and the formation of Paulownia witches' broomYabing Cao, Guiling Sun, Xiaoqiao Zhai, et al.
Cancer Research and Treatment|October 5, 2018
Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 TrialXueying Li, He Huang, Bing Xu, et al.
Nature Communications|August 22, 2023
Longitudinal high-dimensional analysis identifies immune features associating with response to anti-PD-1 immunotherapyElaine Lai-Han Leung, Run-Ze Li, Xing-Xing Fan, et al.
Pageof 5